145 related articles for article (PubMed ID: 22410380)
1. A race-based detour to personalized medicine.
Collier R
CMAJ; 2012 Apr; 184(7):E351-3. PubMed ID: 22410380
[No Abstract] [Full Text] [Related]
2. Race-based therapeutics.
Bloche MG
N Engl J Med; 2004 Nov; 351(20):2035-7. PubMed ID: 15533852
[No Abstract] [Full Text] [Related]
3. Bidil: recontextualizing the race debate.
Séguin B; Hardy B; Singer PA; Daar AS
Pharmacogenomics J; 2008 Jun; 8(3):169-73. PubMed ID: 18195727
[No Abstract] [Full Text] [Related]
4. Medicine. Race and reification in science.
Duster T
Science; 2005 Feb; 307(5712):1050-1. PubMed ID: 15718453
[No Abstract] [Full Text] [Related]
5. Gray area for new heart failure drug. Although the FDA approved BiDil for blacks with heart failure, it may work in anyone.
Harv Heart Lett; 2005 Nov; 16(3):1-2. PubMed ID: 16363036
[No Abstract] [Full Text] [Related]
6. Colour-coded cures.
Kingsland J
New Sci; 2005 Jun 11-17; 186(2503):42-7. PubMed ID: 16178100
[No Abstract] [Full Text] [Related]
7. U.S. to review drug intended for one race.
Saul S
N Y Times Web; 2005 Jun; ():A1, A15. PubMed ID: 15966118
[No Abstract] [Full Text] [Related]
8. Grassroots marketing in a global era: more lessons from BiDil.
Rusert BM; Royal CD
J Law Med Ethics; 2011; 39(1):79-90. PubMed ID: 21314797
[No Abstract] [Full Text] [Related]
9. Pharmacogenetics, race and global injustice.
Holm S
Dev World Bioeth; 2008 Aug; 8(2):82-8. PubMed ID: 19143085
[TBL] [Abstract][Full Text] [Related]
10. The paradox of race in the Bidil debate.
Crawley L
J Natl Med Assoc; 2007 Jul; 99(7):821-2. PubMed ID: 17668653
[No Abstract] [Full Text] [Related]
11. Not black and white: BiDil may work best for African Americans--but do we know why?
New Sci; 2005 Jun 11-17; 186(2503):3. PubMed ID: 16178098
[No Abstract] [Full Text] [Related]
12. Drug success signals a new trend. A "race-based" medication is a step toward individualized care.
Heart Advis; 2005 Apr; 8(4):4-5. PubMed ID: 16138392
[No Abstract] [Full Text] [Related]
13. Drug targeting: is race enough?
Wadman M
Nature; 2005 Jun; 435(7045):1008-9. PubMed ID: 15973367
[No Abstract] [Full Text] [Related]
14. Race as a proxy for drug response: the dangers and challenges of ethnic drugs.
Bowser R
De Paul Law Rev; 2004; 53(3):1111-26. PubMed ID: 16211761
[No Abstract] [Full Text] [Related]
15. Pharmacogenetics and ethnically targeted therapies: racial drugs need to be put in context.
Kahn JD
BMJ; 2005 Jun; 330(7506):1508; author reply 1508. PubMed ID: 15976430
[No Abstract] [Full Text] [Related]
16. A cure for a race? Heart drug findings set off ethics debate.
Payne JW
Washington Post; 2004 Nov; ():F1, F4. PubMed ID: 15700369
[No Abstract] [Full Text] [Related]
17. BiDil for heart failure in black patients: The U.S. Food and Drug Administration perspective.
Temple R; Stockbridge NL
Ann Intern Med; 2007 Jan; 146(1):57-62. PubMed ID: 17200223
[TBL] [Abstract][Full Text] [Related]
18. Color blind, or just plain blind?
Czap A
Altern Med Rev; 2005 Jun; 10(2):81-2. PubMed ID: 16032786
[No Abstract] [Full Text] [Related]
19. Introduction: Facts and fictions: BiDil and the resurgence of racial medicine.
Dorr GM; Jones DS
J Law Med Ethics; 2008; 36(3):443-8. PubMed ID: 18840234
[No Abstract] [Full Text] [Related]
20. BiDil for heart failure in black patients.
Kahn JD
Ann Intern Med; 2007 Aug; 147(3):215; author reply 215-6. PubMed ID: 17679713
[No Abstract] [Full Text] [Related]
[Next] [New Search]
